Brief: Nxera Pharma Secures Exclusive Rights To Fabry Disease Phase 3 Oral Therapy Candidate Lucerastat For Japan
28/10/2026 07:54
BRIEF-Nxera Pharma Secures Exclusive Rights To Fabry Disease Phase 3 Oral Therapy Candidate Lucerastat For Japan Oct 28 (Reuters) - Nxera Pharma Co., Ltd. 4565.T:
NXERA PHARMA SECURES EXCLUSIVE RIGHTS TO FABRY DISEASE PHASE 3 ORAL THERAPY CANDIDATE LUCERASTAT FOR JAPAN AND SELECTED ASIA PACIFIC MARKETS
Source text: ID:nGNX6Qk12V
Further company coverage: 4565.T
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nxera Pharma
See all newsTable: Nxera Pharma -9-MTH group results (IFRS)
Brief: Nxera Pharma Secures Exclusive Rights To Fabry Disease Phase 3 Oral Therapy Candidate Lucerastat For Japan
Nxera Pharma Secures Exclusive Rights To Fabry Disease Phase 3 Oral Therapy Candidate Lucerastat For Japan And Selected Asia Pacific Markets
Development And Commercialization Agreement With Nxera
Nxera Pharma Submits Marketing Authorization Application For Vamorolone In South Korea For Treatment Of Duchenne Muscular Dystrophy